Onderneming NeuroVive Pharmaceutical AB Swiss Exchange
Aandelen
NVP
SE0002575340
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
SEK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Mitochondrial Diseases
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +341,94% |
Verkoop per regio
SEK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Sweden
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +341,94% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ellen Donnelly
CEO | Chief Executive Officer | 50 | 03-02-21 |
Eskil Elmér
FOU | Founder | 54 | 01-02-00 |
Director of Finance/CFO | 57 | 01-12-13 | |
Dag Nesse
CTO | Chief Tech/Sci/R&D Officer | 58 | 01-02-23 |
Magnus Hansson
CTO | Chief Tech/Sci/R&D Officer | 48 | 01-01-08 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 70 | 28-04-16 | |
David Bejker
BRD | Director/Board Member | 49 | 27-04-17 |
Eskil Elmér
FOU | Founder | 54 | 01-02-00 |
Roger Franklin
BRD | Director/Board Member | 45 | 20-05-20 |
Denise Goode
BRD | Director/Board Member | 66 | 27-04-18 |
Director/Board Member | 64 | 27-04-17 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 1 056 299 165 | 930 212 762 ( 88,06 %) | 0 | 88,06 % |
Bedrijfsgegevens
![Adres NeuroVive Pharmaceutical AB(NVP)](https://cdn.zonebourse.com/static/address/11050616.png)
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,45% | 122 mld. | |
+21,96% | 116 mld. | |
+25,76% | 27,03 mld. | |
-20,05% | 20,36 mld. | |
-16,28% | 15,91 mld. | |
-15,96% | 16,43 mld. | |
-44,35% | 15,6 mld. | |
+63,91% | 14,94 mld. | |
+2,52% | 13,59 mld. |